BACKGROUND: Neoadjuvant chemotherapy is used in the treatment of breast carcinoma because it substantially reduces the size of the primary tumor and lymph node metastases. The present study investigated biomarkers that can predict a pathologic response to the therapy. MATERIAL/METHODS: The role of apoptosis in regression of the tumors after neoadjuvant chemotherapy was determined by TUNEL and anti-active caspase 3 assay. The transcriptional profile of 84 key apoptosis genes was evaluated in both pre-therapeutically obtained tumor tissue by core needle biopsy and in specimens removed by final surgery, using a pathway-specific real-time PCR assay. Obtained data were analyzed by hierarchical cluster analysis and correlation analysis. The immunohistochemical profile of each tumor was determined using the standard ABC method. RESULTS: On the basis of a hierarchical cluster analysis of 13 significantly changed genes, we divided patients into good and poor prognosis groups, which correlate well with progression-free survival. In the good prognosis group, we found a statistically significant down-regulation of the expression of MCL1 and IGF1R genes after neoadjuvant treatment. We also found a statistically significant overexpression of BCL2L10, BCL2AF1, CASP8, CASP10, CASP14, CIDEB, FADD, HRK, TNFRSF25, TNFSF8 and CD70 genes. In contrast, we found up-regulation of IGF1R after the treatment in the group with poor prognosis. CONCLUSIONS: Gene expression profiling using real-time PCR assay is a valuable research tool for the investigation of molecular markers, which reflect tumor biology and treatment response.

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005;55:74–108. PubMed

Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for Brest carcinoma. Cancer. 2003;98:1150–60. PubMed

Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res. 2004;10:5988–97. PubMed

Goldhirsch A, Glick JH, Gelber RD, et al. Meeting Highlights: Intemationa1 Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol. 2005;16:1569–83. PubMed

Eifel P, Axelson JA, Costa J, et al. NIH Consensus Development Panel: Adjuvant Therapy for Breast Cancer. J Natl Cancer Inst. 2001;93:979–89. PubMed

Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol. 2010;7:725–32. PubMed

Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59:225–31. PubMed PMC

Sotiriou C, Powles TJ, Dowsett M, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002;4:R3. PubMed PMC

Pluciennik E, Krol M, Nowakowska M, et al. Breast cancer relapse prediction based on multi-gene RT-PCR algorithm. Med Sci Monit. 2010;16(3):CR132–36. PubMed

Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52. PubMed

Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74. PubMed PMC

Sotiriou C, Neo SY, McShane LM, et al. Breast cancer c1assification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–98. PubMed PMC

van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profi1ing predicts c1inical outcome of breast cancer. Nature. 2002;415:530–36. PubMed

Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol. 2009;20:1319–29. PubMed PMC

Tavassoli FA, Devilee P. WHO Classification of tumours Pathology and genetics tumours of the breast and female genital organs. Lyon: IARC Press; 2004.

Normanno N, De Luca A, Carotenuto P, et al. Prognostic Applications of Gene Expression Signatures in Breast Cancer. Oncology. 2009;77(Suppl 1):2–8. PubMed

Skálová H, Dundr P, Povýšil C, et al. Altered expression of Her2/neu after neoadjuvant treatment of breast cancer. Folia Biologica. 2011;57(5):191–99. PubMed

Tvrdík D, Svatošová J, Dundr P, Povýšil C. Molecular diagnosis of synovial sarcoma: detection of SYT-SSX1/2 fusion transcripts by RT-PCR in paraffin-embedded tissue. Med Sci Monit. 2005;11(3):MT1–7. PubMed

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8. PubMed

Li Z, Liu B, Maminishkis A, et al. Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol. 2008;181:5147–57. PubMed PMC

Duan WR, Garner DS, Williams SD, et al. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 2003;199:221–28. PubMed

Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 2010;10:228–40. PubMed PMC

Van de Vijver M. Gene-Expression Profiling and the Future of Adjuvant Therapy. The Oncologist. 2005;10(Suppl 2):30–34. PubMed

Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–69. PubMed

Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73:2013–26. PubMed

Leist M, Jäättelä M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001;2:589–98. PubMed

Sperandio S, de Belle I, Bredesen DE. An alternative, non-apoptotic form of programmed cell death. Proc Natl Acad Sci USA. 2000;97:14376–81. PubMed PMC

Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett. 2011

Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia. 2001;15:1022–32. PubMed

Inohara N, Ding L, Chen S, Núńez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L) EMBO J. 1997;16:1686–94. PubMed PMC

Rocha RL, Hilsenbeck SG, Jackson JG, et al. Insulin-like growth factor binding protein 3 and insulin receptor substrate 1 in breast cancer: correlation with clinical parameters and disease-free survival. Clinical Cancer Research. 1997;3:103–9. PubMed

Turner BC, Haffty BG, Narayanan L, et al. IGF-I receptor and cyclin D1 expression influence cellular radiosensitivity and local breast cancer recurrence after lumpectomy and radiation. Cancer Research. 1997;57:3079–83. PubMed

Inohara N, Koseki T, Chen S, et al. CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J. 1998;17:2526–33. PubMed PMC

Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43–50. PubMed

Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 1997;89:175–84. PubMed

Liu X, Li P, Widlak P, et al. The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci USA. 1998;95:8461–66. PubMed PMC

Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998;391:96–99. PubMed